MCID: PLM196
MIFTS: 34

Pulmonary Adenocarcinoma in Situ

Categories: Cancer diseases

Aliases & Classifications for Pulmonary Adenocarcinoma in Situ

MalaCards integrated aliases for Pulmonary Adenocarcinoma in Situ:

Name: Pulmonary Adenocarcinoma in Situ 12 15
Bronchioalveolar Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050870

Summaries for Pulmonary Adenocarcinoma in Situ

Disease Ontology : 12 A lung carcinoma in situ that derives from the distal bronchioles or alveoli that initially exhibit a specific non-invasive growth pattern.

MalaCards based summary : Pulmonary Adenocarcinoma in Situ, also known as bronchioalveolar carcinoma, is related to adenocarcinoma in situ and bronchiolo-alveolar adenocarcinoma. An important gene associated with Pulmonary Adenocarcinoma in Situ is LINC02288 (Long Intergenic Non-Protein Coding RNA 2288), and among its related pathways/superpathways are p70S6K Signaling and Pathways in cancer. The drugs Promethazine and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and thyroid, and related phenotypes are neoplasm and reproductive system

Related Diseases for Pulmonary Adenocarcinoma in Situ

Diseases related to Pulmonary Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 118)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma in situ 30.2 KRAS HRAS EGFR ALK
2 bronchiolo-alveolar adenocarcinoma 30.1 SLC27A5 NKX2-1 KRAS EGFR
3 thymoma 29.7 NKX2-1 HRAS EGFR EGF
4 adenocarcinoma 29.0 NKX2-1 KRAS HRAS EGFR EGF ALK
5 lung cancer susceptibility 3 27.1 SLC27A5 SFTPC NKX2-1 KRAS HRAS EML4
6 signet ring basal cell carcinoma 10.5 KRAS HRAS
7 trachea carcinoma in situ 10.5 KRAS HRAS
8 cobblestone retinal degeneration 10.5 KRAS HRAS
9 nasal cavity adenocarcinoma 10.5 KRAS HRAS
10 ampulla of vater neoplasm 10.5 KRAS HRAS
11 descending colon cancer 10.4 KRAS HRAS
12 periampullary adenoma 10.4 KRAS HRAS
13 transverse colon cancer 10.4 KRAS HRAS
14 appendiceal neoplasm 10.4 KRAS HRAS
15 gallbladder benign neoplasm 10.4 KRAS HRAS
16 myh-associated polyposis 10.4 KRAS HRAS
17 appendix adenocarcinoma 10.4 KRAS HRAS
18 wolffian duct adenocarcinoma 10.4 KRAS HRAS
19 ascending colon cancer 10.4 KRAS HRAS
20 biliary tract benign neoplasm 10.4 KRAS HRAS
21 tumor of exocrine pancreas 10.4 KRAS HRAS
22 pancreatic acinar cell adenocarcinoma 10.4 KRAS HRAS
23 endosalpingiosis 10.4 KRAS HRAS
24 core binding factor acute myeloid leukemia 10.4 KRAS HRAS
25 appendix disease 10.3 KRAS HRAS
26 duodenum adenocarcinoma 10.3 KRAS HRAS
27 bile duct cysts 10.3 KRAS HRAS
28 acneiform dermatitis 10.3 KRAS HRAS EGFR
29 paronychia 10.3 KRAS HRAS EGFR
30 skin papilloma 10.3 KRAS HRAS EGFR
31 anus cancer 10.3 KRAS HRAS EGFR
32 uterine body mixed cancer 10.3 KRAS HRAS EGFR
33 mixed cell type cancer 10.3 KRAS HRAS EGFR
34 nonmucinous bronchioloalveolar adenocarcinoma 10.3 SLC27A5 NKX2-1
35 rectum adenocarcinoma 10.3 KRAS HRAS EGFR
36 ovarian cystadenocarcinoma 10.3 KRAS HRAS EGFR
37 colonic benign neoplasm 10.3 KRAS HRAS EGFR
38 uterine corpus cancer 10.3 KRAS HRAS EGFR
39 appendix cancer 10.3 KRAS HRAS
40 exanthem 10.3 KRAS HRAS EGFR
41 penile cancer 10.3 KRAS HRAS EGFR
42 lymphangioma 10.3 KRAS HRAS EGFR
43 large intestine adenocarcinoma 10.3 KRAS HRAS
44 intestinal benign neoplasm 10.3 KRAS HRAS EGFR
45 carcinosarcoma 10.3 KRAS HRAS EGFR
46 gastrointestinal system benign neoplasm 10.3 KRAS HRAS EGFR
47 bile duct adenocarcinoma 10.3 KRAS HRAS EGFR
48 colorectal adenoma 10.2 KRAS HRAS EGFR
49 retinitis pigmentosa 11 10.2 SLC27A5 HRAS EGFR
50 pulmonary fibrosis 10.2

Graphical network of the top 20 diseases related to Pulmonary Adenocarcinoma in Situ:



Diseases related to Pulmonary Adenocarcinoma in Situ

Symptoms & Phenotypes for Pulmonary Adenocarcinoma in Situ

MGI Mouse Phenotypes related to Pulmonary Adenocarcinoma in Situ:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.43 ALK EGFR HRAS KRAS NKX2-1 SFTPC
2 reproductive system MP:0005389 9.23 ALK CALR3 DELE1 EGF EGFR KRAS

Drugs & Therapeutics for Pulmonary Adenocarcinoma in Situ

Drugs for Pulmonary Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 15)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Promethazine Approved, Investigational Phase 2 60-87-7 4927
2
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
3
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
4
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
5
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
6
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
7 Histamine H1 Antagonists Phase 2
8 Histamine Antagonists Phase 2
9 Antineoplastic Agents, Immunological Phase 2
10 Protein Kinase Inhibitors Phase 2
11 Albumin-Bound Paclitaxel Phase 2
12 Tubulin Modulators Phase 2
13 Antimitotic Agents Phase 2
14
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
15 Mitogens Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase II Study of C225 (Cetuximab) for the Treatment of Patients With Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features Completed NCT00103207 Phase 2
2 Phase II Trial of Chronic Oral ZD1839 (Iressa®) (NSC-715055) in Both Previously-Untreated and Previously-Treated Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) Completed NCT00029003 Phase 2 gefitinib
3 Phase II Study on TAXOL in Bronchioalveolar Carcinoma Completed NCT00002972 Phase 2 paclitaxel
4 ERLOTINIB, A TYROSINE KINASE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AS FIRST LINE TREATMENT, IN PATIENTS WITH LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER (NSCLC). A PHASE II STUDY Completed NCT00615758 Phase 2 Erlotinib

Search NIH Clinical Center for Pulmonary Adenocarcinoma in Situ

Genetic Tests for Pulmonary Adenocarcinoma in Situ

Anatomical Context for Pulmonary Adenocarcinoma in Situ

MalaCards organs/tissues related to Pulmonary Adenocarcinoma in Situ:

40
Lung, Lymph Node, Thyroid, Skin

Publications for Pulmonary Adenocarcinoma in Situ

Articles related to Pulmonary Adenocarcinoma in Situ:

(show top 50) (show all 78)
# Title Authors PMID Year
1
Adamantyl pyran-4-one derivatives and their in vitro antiproliferative activity. 61
30953295 2020
2
Bronchioalveolar carcinoma in an adult alpaca (Vicugna pacos). 61
31072321 2019
3
Genomic analyses based on pulmonary adenocarcinoma in situ reveal early lung cancer signature. 61
30453959 2018
4
Construction of an anti-programmed death-ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells. 61
29928397 2018
5
Evidence against a role for jaagsiekte sheep retrovirus in human lung cancer. 61
28107820 2017
6
Lung cancer in which the hypothesis of multi-step progression is confirmed by array-CGH results: A case report. 61
26889224 2016
7
Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation. 61
25970685 2015
8
Palliative embolisation for intrapulmonary shunting in lepidic predominant adenocarcinoma of the lung. 61
26236621 2015
9
Radiographic characterization of primary lung tumors in 74 dogs. 61
24674604 2014
10
Genomic alterations in pulmonary adenocarcinoma in situ in an adolescent patient. 61
24678688 2014
11
[Video-assisted thoracoscopic (VATS) sublobar anatomic resections for lung cancer]. 61
24585198 2014
12
Laser microdissection of the alveolar duct enables single-cell genomic analysis. 61
25309876 2014
13
IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity. 61
23794184 2013
14
Positron emission tomography-computed tomography in the management of lung cancer: An update. 61
24455612 2013
15
Musashi1 as a potential therapeutic target and diagnostic marker for lung cancer. 61
23715514 2013
16
A 75-year-old man with progressive bronchioalveolar carcinoma. 61
23391120 2013
17
Inhibition of cholinergic signaling causes apoptosis in human bronchioalveolar carcinoma. 61
23222296 2013
18
Measurement of Acetylcholine from Cell Lines. 61
27390758 2013
19
Cytogenetic findings in lung cancer that illuminate its biological history from adenomatous hyperplasia to bronchioalveolar carcinoma to adenocarcinoma: A case report. 61
23226769 2012
20
The influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival: an analysis of the Survival, Epidemiology, and End Results database. 61
22528551 2012
21
Ultra-late relapse with a single cerebellar metastasis 10 years after complete surgery for stage IIA non-small cell lung cancer (bronchioalveolar carcinoma). 61
22425928 2012
22
Mesenchymal hamartoma: prenatal and postnatal diagnosis by imaging. 61
23259097 2012
23
Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma. 61
23028479 2012
24
Lobectomy versus sublobar resection for small (2 cm or less) non-small cell lung cancers. 61
22051277 2011
25
Post-mortem findings in Irish culled hounds. 61
21247584 2011
26
Mucinous adenocarcinoma of the lung in association with congenital pulmonary airway malformation. 61
21034957 2010
27
[Resected pleomorphic carcinoma after long-time follow-up]. 61
20662232 2010
28
Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. 61
19908243 2010
29
Histological pattern of primary malignant lung tumours diagnosed in a tertiary care hospital: 10 year study. 61
21198289 2010
30
Survival of pulmonary cancer patients treated surgically. 61
21258281 2010
31
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. 61
18701186 2009
32
Does lobectomy achieve better survival and recurrence rates than limited pulmonary resection for T1N0M0 non-small cell lung cancer patients? 61
18641014 2009
33
The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. 61
18423782 2008
34
Lung cancer screening with low-dose computed tomography: Canadian experience. 61
18186434 2007
35
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 61
17711504 2007
36
Comparison of clinical with pathological nodal staging from systematic mediastinal lymph node dissection in early resectable non-small cell lung cancer. 61
17609822 2007
37
Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report. 61
17410018 2007
38
Assessment of bolus injection protocol with appropriate concentration for quantitative assessment of pulmonary perfusion by dynamic contrast-enhanced MR imaging. 61
17152051 2007
39
Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. 61
17075127 2006
40
[Bronchioalveolar carcinoma: five year survival]. 61
16977966 2006
41
Growth hormone releasing hormone plasmid supplementation, a potential treatment for cancer cachexia, does not increase tumor growth in nude mice. 61
15375378 2005
42
[Clinical investigation of application of lung biopsy in the diagnosis of diffuse pulmonary interstitial disease]. 61
15461843 2004
43
[Bronchorrhea in a case of pneumonic type of bronchioloalveolar carcinoma]. 61
15675272 2004
44
Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer. 61
15289739 2004
45
Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. 61
12458399 2002
46
The new World Health Organization classification of lung tumours. 61
11829087 2001
47
Direct transformation of rodent fibroblasts by jaagsiekte sheep retrovirus DNA. 61
11296288 2001
48
Relationship between the expression of alpha 1-antitrypsinase in bronchioalveolar carcinoma and clinical pathology. 61
12845749 2000
49
Cytologic distinction between bronchioalveolar carcinoma and reactive/reparative respiratory epithelium: a cytomorphometric analysis. 61
9784990 1998
50
[Uninodular bronchioalveolar carcinoma. Apropos of 10 operated cases]. 61
9780627 1998

Variations for Pulmonary Adenocarcinoma in Situ

Expression for Pulmonary Adenocarcinoma in Situ

Search GEO for disease gene expression data for Pulmonary Adenocarcinoma in Situ.

Pathways for Pulmonary Adenocarcinoma in Situ

Pathways related to Pulmonary Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.95 KRAS HRAS EGFR EGF ALK
2 12.68 KRAS HRAS EML4 EGFR EGF ALK
3
Show member pathways
12.58 KRAS HRAS EGFR EGF
4
Show member pathways
12.57 KRAS HRAS EGFR EGF
5
Show member pathways
12.56 KRAS HRAS EGFR EGF
6 12.53 KRAS HRAS EGFR EGF
7
Show member pathways
12.52 KRAS HRAS EGFR EGF
8
Show member pathways
12.4 KRAS HRAS EGFR EGF
9
Show member pathways
12.4 KRAS HRAS EML4 EGFR EGF ALK
10
Show member pathways
12.35 KRAS HRAS EGFR EGF
11
Show member pathways
12.32 KRAS HRAS EGFR EGF
12
Show member pathways
12.32 KRAS HRAS EGFR EGF
13
Show member pathways
12.32 KRAS HRAS EGFR EGF ALK
14
Show member pathways
12.28 KRAS HRAS EML4 EGFR EGF ALK
15
Show member pathways
12.24 KRAS HRAS EGFR EGF
16
Show member pathways
12.24 KRAS HRAS EGFR EGF
17 12.11 KRAS HRAS EGFR EGF
18
Show member pathways
12.06 KRAS HRAS EGFR EGF
19
Show member pathways
12 KRAS HRAS EGFR EGF
20
Show member pathways
11.97 KRAS HRAS EGFR EGF
21 11.86 KRAS HRAS EGFR EGF
22
Show member pathways
11.83 KRAS HRAS EGFR EGF
23
Show member pathways
11.72 KRAS HRAS EGFR EGF
24 11.68 KRAS HRAS EGFR EGF
25 11.65 KRAS HRAS EGFR
26 11.64 KRAS HRAS EGFR EGF
27 11.57 KRAS HRAS EGFR EGF
28 11.54 KRAS HRAS EGFR
29
Show member pathways
11.52 HRAS EGFR EGF
30 11.46 KRAS HRAS EGFR
31 11.22 HRAS EGFR EGF
32 11.19 KRAS HRAS EGFR
33 11.13 KRAS EGFR EGF
34 11.09 KRAS HRAS EGFR EGF
35 10.98 KRAS HRAS
36 10.84 KRAS HRAS EML4 ALK
37 10.76 KRAS HRAS
38 10.69 HRAS EGFR EGF
39
Show member pathways
10.34 KRAS HRAS EGFR EGF
40
Show member pathways
10.2 EGFR EGF

GO Terms for Pulmonary Adenocarcinoma in Situ

Biological processes related to Pulmonary Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 peptidyl-tyrosine phosphorylation GO:0018108 9.67 EGFR EGF ALK
2 MAPK cascade GO:0000165 9.62 KRAS HRAS EGFR EGF
3 liver development GO:0001889 9.54 KRAS HRAS EGFR
4 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.48 EGFR EGF
5 regulation of long-term neuronal synaptic plasticity GO:0048169 9.46 KRAS HRAS
6 epithelial tube branching involved in lung morphogenesis GO:0060441 9.43 NKX2-1 KRAS
7 cerebral cortex cell migration GO:0021795 9.4 NKX2-1 EGFR
8 response to isolation stress GO:0035900 9.26 KRAS HRAS
9 negative regulation of ERBB signaling pathway GO:1901185 9.16 EGFR EGF
10 positive regulation of DNA replication GO:0045740 9.13 HRAS EGFR EGF
11 positive regulation of MAP kinase activity GO:0043406 8.92 KRAS HRAS EGFR EGF

Sources for Pulmonary Adenocarcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....